Ivosidenib (AG-120), an oral IDH1 inhibitor, has shown encouraging activity in patients with advanced IDH1-mutant, chemotherapy-refractory CCA [48,49] (Table 3). The gene discussed is IDH1; the disease is cholangiocarcinoma.